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Management of severe community-acquired 
pneumonia in Brazil: a secondary analysis of an 
international survey
ORIGINAL ARTICLE
INTRODUCTION
Community-acquired pneumonia (CAP) is an important public health 
problem and a significant cause of mortality and morbidity in all age groups.(1,2) 
High mortality rates have been reported, especially in underdeveloped and 
developing countries, such as Brazil, Argentina and India.(3,4) Despite substantial 
progress in the detection of pathogens and in therapeutic options for the 
management of CAP, several issues remain controversial.(1,5) Although different 
models have been used to predict pneumonia severity,(5-9) there is a gap between 
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Objective: This study aimed to 
evaluate Brazilian physicians’ perceptions 
regarding the diagnosis, severity assessment, 
treatment and risk stratification of severe 
community-acquired pneumonia patients 
and to compare those perceptions to 
current guidelines.
Methods: We conducted a cross-
sectional international anonymous 
survey among a convenience sample 
of critical care, pulmonary, emergency 
and internal medicine physicians from 
Brazil between October and December 
2008. The electronic survey evaluated 
physicians’ attitudes towards the 
diagnosis, risk assessment and therapeutic 
interventions for patients with severe 
community-acquired pneumonia.
Results: A total of 253 physicians 
responded to the survey, with 66% from 
Southeast Brazil. The majority (60%) 
of the responding physicians had > 10 
years of medical experience. The risk 
assessment of severe community-acquired 
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pneumonia was very heterogeneous, 
with clinical evaluation as the most 
frequent approach. Although blood 
cultures were recognized as exhibiting 
a poor diagnostic performance, these 
cultures were performed by 75% of 
respondents. In contrast, the presence 
of urinary pneumococcal and Legionella 
antigens was evaluated by less than 1/3 of 
physicians. The vast majority of physicians 
(95%) prescribe antibiotics according 
to a guideline, with the combination of 
a 3rd/4th generation cephalosporin plus a 
macrolide as the most frequent choice.
Conclusion: This Brazilian survey 
identified an important gap between 
guidelines and clinical practice and 
recommends the institution of educational 
programs that implement evidence-based 
strategies for the management of severe 
community-acquired pneumonia.
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the recommended guidelines and current practice for the 
management of CAP. The association of clinical scores and 
biomarkers appears to be better for predicting short-and 
long-term morbidity and mortality.(10,11) The major 
challenge for physicians is to translate the recommended 
guidelines into clinical practice.(12,13) This study aims to 
answer some questions that remain controversial and help 
in the decision-making process.
We conducted a secondary analysis of Brazilian data 
from an international survey that evaluated physicians’ 
perceptions regarding practice in the context of the 
diagnosis, severity assessment, treatment and risk 
stratification of severe CAP.(14)
METHODS
In this study, we analyzed 253 (54% of respondents) 
questionnaires that were extracted from a previous 
international survey and corresponded to the Brazilian 
cohort. The Local Ethics Committee from Instituto 
Nacional de Câncer approved the study (Nº 105/08). A 
full description of the survey development is detailed 
elsewhere.(14)
We performed a detailed description of current 
practices and performed comparisons to evaluate clinicians’ 
adherence to guidelines and the current implementation 
of guidelines in the treatment of CAP patients.
In Brazil, an invitation to answer the survey and the 
associated web link were sent by email to a convenience 
sample of intensive care unit (ICU) and pulmonary care 
physicians listed in the Brazilian Research in Intensive 
Care Network (BRICNet), the Brazilian Society of 
Pulmonary Diseases, the Associación Latino Americana 
del Tórax (ALAT) and the personal mailing lists of the 
investigators.
Data and statistical analysis
The survey results were exported into a Microsoft 
Excel template and analyzed using the Statistical Package 
for Social Science (SPSS) 13.0 software package (Chicago, 
Illinois, USA). Standard descriptive statistics were used, as 
appropriate. The variables are reported as the number (%). 
As the number of respondents varied across the questions, 
the proportions displayed in the results section and tables 
were not constant. Fischer’s exact test was used to compare 
the variables. A two sided p-value of < 0.05 was considered 
to be significant.
RESULTS
Demographics
A total of 253 questionnaires were available for 
analysis, with 66% of the questionnaires from Southeast 
Brazil, 12% of the questionnaires from South Brazil, 
10% of the questionnaires from Northeast Brazil, 4% 
of the questionnaires from North Brazil and 1% of the 
questionnaires from Midwest Brazil. The demographic 
characteristics of the respondents are described in table 1.
The majority (60%) of the responding physicians 
had > 10 years of medical experience. A total of 18% 
of physicians worked primarily in university-affiliated 
hospitals, and 43% worked primarily in private hospitals. 
The physicians’ medical experience in critical care was 
quite high, with 47% of the respondents reporting > 10 
years and 27% of the respondents reporting between 5 
Table 1 - Characteristics of the responding physicians
Characteristics N (%)
Duration of experience (years) N = 253
< 5 41 (16)
5 - 10 61 (24)
> 10 151 (60)
Primary specialty N = 253
Pneumology 66 (26)
Intensive care 97 (38)
Other 90 (36)
Experience in critical care (years) N = 185
< 5 50 (27)
5 - 10 49 (26)
> 10 86 (47)
Hospital size (beds) N = 239
< 250 124 (52)
250 - 500 81 (34)
> 500 34 (14)
Intensive care unit size (beds) N = 220
< 10 89 (40)
10 - 20 74 (34)
> 20 57 (26)
Documented CAP patient volume N = 207
< 10 18 (9)
10 - 50 125 (60)
> 50 64 (31)
ICU - intensive care unit; CAP - community-acquired pneumonia. Results are expressed 
as the N (%).
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and 10 years of practice in this specialty. A total of 193 
respondents reported an average ICU occupancy rate > 
75%, with 150 respondents reporting a rate above 85%.
Risk assessment and diagnostic practices
The criteria used by the physicians to define the severity 
of CAP were heterogeneous (Figure 1), and the presence of 
shock, the need for mechanical ventilation (MV) and ICU 
admission were the most frequently reported measures 
for classifying CAP. Physicians regularly performed risk 
stratification in CAP patients using clinical evaluation 
(Figure 2). Structured severity assessment tools were used 
systematically in less than 40% of cases. A total of 52% 
of physicians reported using severity scores to support 
decisions concerning whether CAP patients should be 
admitted to the ICU or the medical ward.
Figure 1 - Variables used by physicians to define the severity of community-acquired 
pneumonia. MV - mechanical ventilation; RR - respiratory rate; CAP - community-acquired pneumonia.
Figure 2 - Risk assessment of community-acquired pneumonia. PSI - Pneumonia 
Severity Index; APACHE - acute physiology and chronic health evaluation; ATS - American Thoracic Society; 
SAPS - simplified acute physiology score; CAP - community-acquired pneumonia.
The use of biomarkers to assess CAP severity was also 
evaluated. Seventy-one percent of the respondents routinely 
used laboratory tests or biomarkers, specifically C-reactive 
protein (CRP) (47%) and procalcitonin (PCT) (8%).
In the emergency department, > 75% of patients with 
CAP undergo SaO2 measurement, as reported by 53% of 
responding physicians.
We also assessed the diagnostic workflow. For CAP 
patients admitted to the hospital, the majority of 
respondents performed blood cultures (75%). However, 
the collection of respiratory samples was performed less 
frequently: sputum cultures were collected in 32% of 
cases, tracheal aspirates were collected in 39% of cases and 
bronchoalveolar lavage was performed (BAL) in 34% of 
cases. With respect to these samples, 33% of respondents 
reported performing a Gram stain. In addition, 14% and 
20% of physicians reported asking for pneumococcal 
and Legionella urinary antigen tests, respectively. Overall, 
15% of respondents required routine serology for atypical 
pathogens. C-reactive protein was used routinely to 
support the clinical diagnosis by 29% of respondents.
In this survey, we investigated the perceived rate of 
pneumonia caused by atypical pathogens. Concerning the 
prevalence of Legionella, 62 respondents (33%) had no 
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data and 42% of respondents reported that this pathogen 
occurred in less than 10% of cases. For patients receiving 
invasive mechanical ventilation, the diagnostic workflow 
was similar to the workflow described above. The 
answers concerning the microbiological documentation 
of CAP varied widely: 18% of clinicians reported that 
microbiological documentation occurred in less than 10% 
of patients, 38% of clinicians reported that microbiological 
documentation occurred in 10 - 25% of patients, 34% of 
clinicians reported that microbiological documentation 
occurred in 25-50% of patients, and 10% of clinicians 
reported that > 50% of patients have microbiological 
documentation.
As expected, 42% of the respondents reported lung 
biopsy as an unusual practice (< 3 biopsies/year) and half 
of the respondents never used lung biopsy as a diagnostic 
practice.
Therapeutic management of severe 
community-acquired pneumonia
Regarding the prescription of antibiotics for patients 
with CAP, nearly all (97%) respondents used a guideline 
for the initial choice of an antibiotic regimen: 32% used 
the American Thoracic Society/Infectious Diseases Society 
of America, 36% used national guidelines, and 30% used 
local guidelines. Some physicians used other guidelines 
from the Centers for Disease Control and Prevention 
(CDC) or recommendations present in classic handbooks, 
such as the “Sanford Manual of Antimicrobial Therapy.”
The primary antibiotic regimen was a β-lactam 
plus a macrolide in 38% of cases, a 3rd/4th generation 
cephalosporin plus a macrolide in 38% of cases, a β-lactam 
plus a quinolone in 10% of cases, a quinolone in 7% of 
cases, an anti-pseudomonal agent plus a macrolide in 5% 
of cases, a 3rd/4th generation cephalosporin in 2% of cases 
and a β-lactam in 0.5% of cases.
The approximate duration of antibiotic therapy was up 
to 8 days in 29% of cases, 9 - 14 days in 64% of cases and 
> 14 days in 6% of cases. In CAP patients, antibiotics 
were primarily stopped using clinical criteria (68%). A 
CRP course was used in 28% of cases, and a PCT course 
was used in 2% of cases. Only 5% of respondents reported 
that they did not use any biomarker in the assessment of 
clinical course.
To assess the response of CAP to antibiotics, 72% 
of respondents relied on different clinical criteria: 
the improvement of hypoxemia was used by 59% of 
respondents, radiologic improvement was used by 41% of 
respondents, apyrexia was used by 62% of respondents, the 
resolution of shock was used by 55% of respondents, and a 
decrease in the amount and purulence of tracheobronchial 
secretions was used by 49% of respondents.
The monitoring of biomarkers as surrogate markers 
of the response to treatment in patients with severe 
CAP was also reported, with CRP decreasing in 42% of 
patients, the CRP-ratio decreasing in 15% of patients and 
cytokines decreasing in 2% of patients. Other methods 
were mentioned by only 4% of physicians (i.e., respiratory 
rate, white cell count, the ratio of arterial oxygen 
concentration to the fraction of inspired oxygen, and the 
level of consciousness).
The time from the prescription of an antibiotic to the 
first assessment of clinical response was also heterogeneous: 
8% of physicians assessed the clinical response after 24 
hours, 55% of physicians assessed the clinical response 
after 48 hours, 35% of physicians assessed the clinical 
response after 72 hours, 2% of physicians assessed the 
clinical response on the 5th day and 0.5% of physicians 
assessed the clinical response on the 7th day. Only 5% 
of the physicians reported that they never prescribe 
steroids. Among the physicians who prescribed steroids, 
the main reasons for steroid administration were adrenal 
insufficiency (30%), refractory shock (30%) and acute 
respiratory distress syndrome (ARDS) (18%).
The criteria for weaning steroids were also variable. 
A quarter of the physicians stopped steroids according 
to a pre-determined schedule, other physicians stopped 
steroids after the resolution of shock (56%) or hypoxemia 
(18%) and 1% of the physicians stopped steroids at 
the time of ICU discharge. The assessment of adrenal 
function was performed by 25% of physicians for CAP 
patients with septic shock and by 4% of physicians during 
the treatment of CAP patients with ARDS.
Non-invasive ventilation (NIV) was never used in 
CAP patients by 8% of physicians. Among the physicians 
that considered using NIV, 23% used NIV in less than 
10% of patients, 24% used NIV in 10 - 25% of patients, 
27% used NIV in > 25 - 50% of patients, and 12% used 
NIV in > 50 - 75% of patients. In addition, 15% of the 
physicians used NIV in over 75% of CAP patients.
No differences in clinical practice were observed 
when the physicians were compared based on 
professional experience, when specialists were compared 
to non-specialists and when physicians working in a 
university hospital were compared to physicians working 
in other types of hospitals.
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DISCUSSION
We conducted a secondary analysis of an international 
survey that evaluated the perceived management of the 
diagnosis, risk assessment and treatment of severe CAP 
in Brazil. The main purpose was to establish physicians’ 
perceptions regarding the care of patients with severe CAP 
in Brazilian ICUs. No differences in clinical practices were 
observed when we evaluated professional experience, being 
board certified in the specialty or working in a university 
hospital.
The risk assessment of severe CAP was very 
heterogeneous in our sample, and clinical evaluation 
was the most frequent method of severity assessment for 
patients with severe CAP. Structured severity assessment 
tools were used systematically in less than 40% of cases. 
These results are consistent with British Thoracic Society 
guidelines,(15) but the CURB65 score (or another validated 
scoring system) was not routinely applied in conjunction 
with clinical judgment.(15) Brazilian guidelines suggest 
the use of the American Thoracic Society’s criteria for 
severe CAP; these guidelines describe major and minor 
criteria and define the presence of 1 major or 2 minor 
criteria as sufficient for the assessment of severity.(16) The 
major criteria are invasive mechanical ventilation and 
septic shock, which are represented by the most frequent 
physician answers.(16,17) The minor criteria are PaO2/FiO2 
< 250, multilobar involvement, systolic blood pressure 
< 90mmHg and diastolic blood pressure < 60mmHg.(16,17)
The accuracy of scoring systems, such as the 
Pneumonia Severity Index (PSI) and CURB-65, for 
predicting outcomes is questionable.(18) Thus, it is essential 
to identify new tools to help physicians assess patient 
outcomes and stratify the risk of CAP. Novel biomarkers, 
such as cortisol, pro-adrenomedullin and endothelin-1, 
have been shown to be associated with disease severity and 
short-term outcomes in patients with CAP.(18)
Pneumococcal and Legionella urine antigen tests are 
recommended for all patients with severe CAP by the 
British Thoracic Society guidelines.(15) In our population, 
only 14% and 20% of physicians asked for these tests, 
respectively. A secondary analysis of an international 
database reported an incidence of atypical pathogens of 
21% among CAP patients in Latin America.(19) Better 
outcomes, such as a shorter time to clinical stability, a 
shorter length of hospital stay and lower hospital mortality, 
were demonstrated in the subgroup of patients who were 
treated with atypical coverage.(19)
The vast majority of the physicians (95%) stated that 
the prescription of antibiotics is performed according to 
the available guidelines. The combination of a β-lactam or 
a 3rd/4th generation cephalosporin plus a macrolide was the 
most frequent choice (76%); this approach is consistent 
with the British Thoracic Society and the Infectious 
Diseases Society of America guidelines for the treatment 
of SCAP. A total of 64% of the Brazilian physicians 
stated that antibiotic therapy was prescribed for between 
8 and 14 days of treatment, although the international 
recommendation considers a seven-day course to be 
sufficient and safe.(20) This finding can be explained by the 
use of clinical criteria to determine the therapy duration 
and the low use of biomarkers for monitoring the response.
In developing countries, the implementation of clinical 
protocols could improve compliance with best practices 
in sepsis management and improve outcomes.(21) A recent 
study that was performed in ten private hospitals from 
Brazil involved the implementation of a multifaceted sepsis 
education program. That study reported that compliance 
with the resuscitation bundle was associated with a lower 
risk of hospital mortality and was also cost-effective.(21)
Concerning the use of steroids, the British Thoracic 
Society guidelines do not recommend steroid use for the 
routine treatment of severe CAP. In this survey, only 5% of 
the physicians reported never prescribing steroids. The main 
reasons for the use of steroids were refractory septic shock 
and adrenal insufficiency, which occur in severely ill patients 
with severe sepsis and septic shock. This practice could be a 
reflection of the Surviving Sepsis Campaign guidelines (SSC 
2004 and 2008) that recommended adjunctive therapy with 
low-dose steroids in septic shock patients.
Guidelines differ concerning the use of NIV in severe 
CAP patients. The British Thoracic Society guidelines state 
that neither NIV nor continuous positive airway pressure 
(CPAP) should be used routinely in the management of 
patients with respiratory failure due to CAP. Additionally, 
these guidelines state that an NIV trial can be performed, 
but this trial should only be conducted in a critical care 
area, with the possibility for a rapid switch to invasive 
ventilation. In this survey, NIV was never used by 8% of 
physicians. We found that NIV is used in a large percentage 
of patients; this finding should be evaluated in a secondary 
analysis. In a future study, the questions concerning NIV 
should focus on the co-existence of other respiratory 
diseases, such as chronic obstructive pulmonary disease, 
or end-stage diseases, such as lung cancer, which might 
determine the choice of NIV in these patients.
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We acknowledge that our study has some limitations. 
One of the main limitations is that this study is a 
retrospective study in which a secondary analysis of a 
survey was performed. There is a temporal limitation 
because the survey was performed in 2008; thus, the 
data were evaluated with an important time delay. The 
sample choice (i.e., a convenience sample of physicians) 
is also a limitation and might generate an important 
bias in the results. The fact that this survey focuses on 
physicians’ perceptions may create another bias because 
the perceptions of the clinicians may not accurately 
represent the real clinical practice scenario. In addition, 
data concerning viral pneumonia were beyond the scope 
of this study. In spite of these limitations, our study 
sheds light on the knowledge of clinical practice for the 
management of CAP in Brazilian ICUs.
CONCLUSION
In conclusion, this survey presented valuable data 
related to the management of severe community-acquired 
pneumonia in Brazilian intensive care units. Although 
heterogeneous approaches were reported, we observed 
an incomplete application of the current literature 
recommendations in clinical practice in all evaluated 
domains. This study identified a gap between guidelines 
and clinical practice and suggests that the implementation 
of educational programs and protocols that include 
evidence-based strategies is needed to improve the 
management of severe community-acquired pneumonia.
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Objetivo: Avaliar a percepção dos médicos brasileiros 
quanto ao diagnóstico, à avaliação de gravidade, ao tratamento 
e à estratificação de risco em pacientes com pneumonia grave 
adquirida na comunidade, e compará-la com as diretrizes atuais.
Métodos: Estudo transversal realizado por meio da aplicação 
de um questionário anônimo a uma amostra de médicos brasileiros 
especialistas em cuidados intensivos, medicina de emergência, 
medicina interna e pneumologia. Entre outubro e dezembro de 
2008, foram avaliadas as atitudes dos médicos no diagnóstico, 
a avaliação de risco e as intervenções terapêuticas para pacientes 
com pneumonia grave adquirida na comunidade.
Resultados: Responderam ao questionário 253 médicos, 
sendo 66% da Região Sudeste do Brasil. A maioria (60%) dos 
médicos que responderam tinha mais de 10 anos de experiência. 
Verificou-se que a avaliação de risco de pneumonia grave 
adquirida na comunidade foi muito heterogênea, sendo a 
avaliação clínica a forma de avaliação de risco mais frequente. 
As hemoculturas foram habitualmente realizadas por 75% dos 
médicos, entretanto, foi reconhecido seu fraco desempenho 
diagnóstico. Por outro lado, a pesquisa de antígenos urinários 
de Pneumococo e Legionella foi solicitada por menos de um 
terço dos médicos. A maioria (95%) prescreveu antibióticos de 
acordo com as diretrizes. A combinação de uma cefalosporina 
de terceira ou quarta geração com um macrolídeo foi a escolha 
mais comum.
Conclusão: Este inquérito brasileiro demonstrou diferenças 
entre as diretrizes publicadas e a prática clínica. Isso leva à necessidade 
de se desenvolverem programas educacionais e de adoção de 
protocolos para implementar estratégias baseadas em evidências no 
manejo da pneumonia grave adquirida na comunidade.
RESUMO
Descritores: Infecções comunitárias adquiridas; Sepse; 
Antimicrobianos; Avaliação de risco; Diagnóstico; Unidades de 
terapia intensiva; Questionários; Brasil
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